The secondary humoral immune response is characterized by plasma B cells secreting isotype-switched and affinity-matured antibodies. The efficient generation of plasma B cells in the GC depends on the presence of follicular helper T (T FH ) cells, a cell type thought to arise from naive CD4-positive T cells by a hitherto unresolved differentiation pathway. Mice deficient for CD155, an adhesion receptor of the immunoglobulin superfamily, are impaired to mount a secondary humoral immune response upon oral administration of antigen, while the primary IgM response is unaffected. Here, we show that mice lacking CD155 harbor significantly reduced numbers of T FH cells in their Peyer's patches. This was paralleled by a decreased frequency of T FH cells in the GC. Moreover, the CD155 ligand CD226, which is involved in T-cell activation, is down-regulated during T FH cell differentiation, resulting in a complete absence of CD226 on those T FH cells residing in the GC. Concurrently, the expression of TIGIT/WUCAM, a newly discovered CD155 ligand, is induced in T FH cells. Thus, these cells replace an activating by a putative inhibitory CD155-binding partner during their differentiation.Key words: CD155 . CD226 . Follicular helper T cells . GC . TIGIT/WUCAM Introduction CD155 represents an Ig-like glycoprotein [1] and is the founder of a subfamily of adhesion receptors comprising also the related nectins 1-4. CD155/nectins take part in the complex regulation of cell growth, differentiation and motility [2,3], thereby in part explaining their identification as tumor markers [4][5][6][7]. Current evidence suggests that in contrast to nectins, CD155 acquired immunologically relevant functions. This apparent, yet not absolute, functional dichotomy in the CD155 family may relate to the observation that CD155 belongs to the category of rapidly evolving genes [8] that may promote the occurrence of new receptor/ligand interactions. In contrast to nectins, CD155 lacks self-adhesion [8]. Instead, CD155 binds to nectin-3 [9], vitronectin [10], CD96 [11,12], CD226 [13] as well as the most recently discovered TIGIT/WUCAM [14,15]. CD155 is broadly expressed among immune cells [16], whereas the expression patterns of the activating receptor CD226 and the potentially inhibitory TIGIT/WUCAM are more restricted. In the T lineage, CD155 is present on T cells of virtually all stages of differentiation, ranging from early thymocytes to the antigen-experienced memory T cells [16]. CD226 is first observed on single positive thymocytes [17] and its subsequent expression is subject to regulation depending on the differentiation path following antigen challenge [18]. Inversely, TIGIT/WUCAM is absent from resting human PBMC and is only expressed upon stimulation [14,15]. Interestingly, immature DC up-regulate CD155 upon stimulation [16], suggesting a role of this receptor in T-cell priming. CD226 was assigned a co-stimulatory capacity [19][20][21] and its interaction with CD155 is pivotal in cytotoxic T/NKdirected lysis of targets such as immature DC...